Cell and gene therapies have emerged as promising therapeutic solutions for treating various life-threatening diseases such as cancer, cardiovascular diseases, neurological disorders, and genetic disorders. Cell therapies involve transplantation of healthy cells into patients to replace dysfunctional or damaged cells, while gene therapies modify or manipulate a patient’s genes to treat a disease. Cell and gene therapies improve the body’s ability to prevent or fight diseases by delivering therapeutic cells or genetic material to target cells or tissues. Some key advantages of cell and gene therapies include their specificity, safety, and effectiveness in targeting the underlying causes of diseases at molecular and cellular levels. The growing prevalence of cancer and other chronic diseases has increased the need for advanced treatment options beyond conventional drug therapies. Additionally, the limitations of small molecule drugs and biologics in effectively treating complex diseases have boosted research into novel cell and gene therapies.

The global Middle East And Asia Pacific Cell And Gene Therapy Market is estimated to be valued at Us$ 3600.53 Mn in 2023 and is expected to exhibit a CAGR Of 15% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One major trend driving growth in the Middle East and Asia Pacific cell and gene therapy market is the rising focus on gene editing technologies. Gene editing technologies like CRISPR/Cas9 allow selective permanent modification of genes to correct mutations or insert desired genes. These technologies have tremendous potential in developing next-generation cell and gene therapies for treating various genetic disorders like sickle cell disease and beta-thalassemia. Leading pharmaceutical and biotech companies are actively collaborating with gene editing technology providers and research institutes to advance the development of novel cell and gene therapies for diseases with high unmet needs. For instance, CRISPR Therapeutics and Vertex Pharmaceuticals are developing CTX001, an investigational CRISPR/Cas9 gene-edited therapy to treat sickle cell disease and transfusion-dependent beta-thalassemia. Such upcoming gene-edited therapies are expected to transform the treatment landscape of genetic and other chronic diseases in the coming years.

Porter’s Analysis

Threat of new entrants: The regulatory barriers and high capital requirements make it difficult for new players to enter this market.

Bargaining power of buyers: There are large pharmaceutical companies that have significant bargaining power over smaller players in this market.

Bargaining power of suppliers: The intellectual property around core technologies gives key suppliers strong bargaining power over buyers.

Threat of new substitutes: There is currently no substitute for cell and gene therapies available. Alternative treatment options have limited ability to substitute these emerging therapies.

Competitive rivalry: The market currently has a few large players. Competition is expected to intensify as more players enter this rapidly growing market space.

Key Takeaways

The Global Middle East And Asia Pacific Cell And Gene Therapy Market Demand is estimated to be valued at US$ 3600.53 Mn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030.

The Middle East and Asia Pacific cell and gene therapy market is expected to witness high growth over the forecast period. The regional markets within Asia Pacific and the Middle East are growing at an impressive pace due to increasing incidence of cancer and other chronic diseases. The China and India markets are expected to be among the fastest growing regional markets due to advancing research infrastructure and rising healthcare spending in these countries. Collaborations between local players and global leaders are also driving market growth.

Key players:

Key players operating in the Middle East and Asia Pacific cell and gene therapy market are Codexis Inc., Abzena, Ltd., Enantis s.r.o, GenScript Biotech Corp., Waters Corporation, PerkinElmer, Inc., Bruker Corporation, Agilent Technologies, Bio-Rad Laboratories Inc., and Thermo Fisher Scientific Inc., among others. These companies are focusing on expanding their presence and capacities in high-growth regional markets through partnerships and acquisitions.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it